Search Results

The 9th Annual Corporate Compliance & Transparency in Life Sciences conference runs 17-18 November 2026 in Zurich. Here is everything you need to register: dates, agenda highlights, confirmed speakers, ticket pricing, and an exclusive 20 percent discount code for Priya Life Science readers.

As the EU AI Act, updated EFPIA codes, and multi-jurisdictional enforcement reshape life sciences, the 9th Annual Corporate Compliance & Transparency in Life Sciences Conference in Zurich sets the critical 2027 benchmark for Irish biopharma leaders.

WuXi Biologics CEO Dr. Chris Chen outlines the company's integrated CRDMO model and the role of proprietary platforms like WuXia TrueSite, WuXiUI, and PatroLab in reducing biopharma development timelines and scaling single-use manufacturing.

Intel has announced a massive €5 billion ($5.7 billion) capital investment at its Leixlip campus in Ireland to expand semiconductor manufacturing capacity, driven by global demand for AI and high-performance computing.

LinkedIn is the most powerful platform for pharmaceutical and life sciences professionals to build authority and reach target customers. This complete guide covers company page setup, what to post, best times to publish, how to grow connections, and how to turn LinkedIn into a consistent pipeline.

Newsletters are the most cost-effective marketing tool for pharmaceutical companies. Unlike social media, a newsletter lands directly in the inbox of every person who chose to hear from you. This step-by-step guide explains how to set one up, what to put in it, and how to reach target customers efficiently.

The annual ASCO conference has delivered landmark clinical trial results, bringing promising survival extensions for pancreatic cancer and targeted lung cancer therapies.

A definitive 5,000-word guide to public relations for pharmaceutical, biotech, and MedTech professionals. Learn how to build a PR strategy from scratch, which tools to use, how to write for journalists and LinkedIn, and the exact frameworks used by the world's leading life science communications teams.

A practitioner-level guide to building genuine professional authority on LinkedIn as a pharmaceutical, biotech, or MedTech professional. Covers profile architecture, content strategy, engagement tactics, thought leadership frameworks, and the exact playbooks used by the most followed life science voices on the platform.

A detailed, practical guide to Ireland's Non-EEA Family Reunification Policy as updated in 2026. Covers the new financial thresholds for all sponsor categories, country-specific waiting periods, step-by-step application process, and a comprehensive pre-application checklist - essential reading for pharmacists, healthcare workers, and life science professionals bringing family to Ireland.

As global competition intensifies, UK life sciences leaders are examining Spain’s thriving Catalonia region for strategies to attract commercial sponsors, streamline regulatory reviews, and revitalize Britain’s clinical trials sector.

A step-by-step compliance-safe LinkedIn guide exclusively for Medical Science Liaisons. Covers profile optimisation, what to post, what never to post, KOL engagement, off-label rules, digital medical affairs strategy, and how to build scientific credibility on LinkedIn without breaching pharmaceutical regulatory guidelines.

A complete step-by-step guide for pharmaceutical, biotech and life science professionals on building a credible, visible personal brand on LinkedIn - without ever crossing compliance lines or risking proprietary data exposure. Covers brand strategy, content pillars, storytelling frameworks, and the exact boundaries every pharma professional must respect.

A detailed step-by-step LinkedIn guide for Regulatory Affairs Specialists, Quality Assurance professionals, Pharmacovigilance Officers, CMC Scientists, and all pharmaceutical compliance professionals. Learn exactly how to frame your regulatory expertise on LinkedIn to attract the right roles, visibility, and recognition - without exposing proprietary submissions or confidential regulatory strategy.